Cardiovascular Risk Biomarkers Found for JSLE Patients
By LabMedica International staff writers Posted on 25 Jun 2019 |
Image: Lupus Erythematosus (LE) Cells are neutrophils that have engulfed lymphocyte nuclei coated with and denatured by antibody to nucleoprotein (Photo courtesy of Dr. Moustafa Abdou).
Systemic lupus erythematosus is an autoimmune disease typically affecting women between the ages of 15 and 50, and symptoms flare up unpredictably. Approximately 20% of cases begin during childhood and in these patients the disease is suggested to be more severe.
Juvenile-onset systemic lupus erythematosus (JSLE) is an autoimmune disorder characterized by immune dysregulation, chronic inflammation and increased cardiovascular risk (CVR). Cardiovascular disease is the leading cause of mortality in JSLE not attributable to lupus flare. Symptoms of this diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs.
A team of scientists working with the University College London (London, UK) to investigated dyslipidemia and CVR in a cohort of JSLE patients using in depth metabolomics and related this to clinical and immune cell profiles and to identify novel biomarkers to predict CVR in these patients. Metabolic biomarker analysis by Nuclear Magnetic Resonance (NMR) and in-depth immune cell phenotyping (30 subsets by flow cytometry) was performed on serum and peripheral blood mononuclear cells (PBMCs) respectively from a discovery cohort of 35 JSLE patients (median age 19 (14-25), 12 males, 23 females) compared with 39 age/sex matched healthy donors (HCs) (median age 18 (16-25), 17 males, 22 females).
The team reported that patient stratification by metabolomic profile using unbiased hierarchical clustering revealed three groups that each had a unique lipoprotein profile, immune cell phenotype and clinical presentation. Group-1 had decreased atheroprotective high-density lipoproteins (HDL) and increased atherogenic very low and low-density lipoproteins (VLDL/LDL). Group-2 had elevated HDL, but reduced VLDL/LDL indicating that these groups could be at high and low CVR respectively. Patients in Group-3 displayed an intermediate CVR but a pro-inflammatory immune cell profile.
Patients in Group-1 had a significant increase in plasmablasts and activated T-cells compared to HCs and had clinical features associated with increased disease activity. This metabolomic patient stratification was validated in a separate JSLE cohort. Importantly ApoB:A1 ratio was identified as a highly predictive biomarker distinguishing between JSLE patients in Group-1 and 2, indicating high and low CVR respectively. Finally, longitudinal analysis revealed that the ApoB:A1 ratio biomarker remained stable over time.
George A. Robinson, PhD, a senior research associate and co-author of the study, said, “Our study identifies ApoB:A1 ratio and metabolomic lipoprotein signatures as potential new biomarkers to predict cardiovascular risk in patients with juvenile-onset SLE. Patient stratification using these biomarkers could provide an opportunity for tailored disease treatments using lipid modification therapy and lifestyle interventions.” The study was presented at the Annual European Congress of Rheumatology held June 12-15, 2019, in Madrid, Spain.
Related Links:
University College London
Juvenile-onset systemic lupus erythematosus (JSLE) is an autoimmune disorder characterized by immune dysregulation, chronic inflammation and increased cardiovascular risk (CVR). Cardiovascular disease is the leading cause of mortality in JSLE not attributable to lupus flare. Symptoms of this diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs.
A team of scientists working with the University College London (London, UK) to investigated dyslipidemia and CVR in a cohort of JSLE patients using in depth metabolomics and related this to clinical and immune cell profiles and to identify novel biomarkers to predict CVR in these patients. Metabolic biomarker analysis by Nuclear Magnetic Resonance (NMR) and in-depth immune cell phenotyping (30 subsets by flow cytometry) was performed on serum and peripheral blood mononuclear cells (PBMCs) respectively from a discovery cohort of 35 JSLE patients (median age 19 (14-25), 12 males, 23 females) compared with 39 age/sex matched healthy donors (HCs) (median age 18 (16-25), 17 males, 22 females).
The team reported that patient stratification by metabolomic profile using unbiased hierarchical clustering revealed three groups that each had a unique lipoprotein profile, immune cell phenotype and clinical presentation. Group-1 had decreased atheroprotective high-density lipoproteins (HDL) and increased atherogenic very low and low-density lipoproteins (VLDL/LDL). Group-2 had elevated HDL, but reduced VLDL/LDL indicating that these groups could be at high and low CVR respectively. Patients in Group-3 displayed an intermediate CVR but a pro-inflammatory immune cell profile.
Patients in Group-1 had a significant increase in plasmablasts and activated T-cells compared to HCs and had clinical features associated with increased disease activity. This metabolomic patient stratification was validated in a separate JSLE cohort. Importantly ApoB:A1 ratio was identified as a highly predictive biomarker distinguishing between JSLE patients in Group-1 and 2, indicating high and low CVR respectively. Finally, longitudinal analysis revealed that the ApoB:A1 ratio biomarker remained stable over time.
George A. Robinson, PhD, a senior research associate and co-author of the study, said, “Our study identifies ApoB:A1 ratio and metabolomic lipoprotein signatures as potential new biomarkers to predict cardiovascular risk in patients with juvenile-onset SLE. Patient stratification using these biomarkers could provide an opportunity for tailored disease treatments using lipid modification therapy and lifestyle interventions.” The study was presented at the Annual European Congress of Rheumatology held June 12-15, 2019, in Madrid, Spain.
Related Links:
University College London
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines